Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006371 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00006371 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT00006371, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
Interventions
- DRUG ketoconazole
- DRUG therapeutic hydrocortisone
- DRUG aminoglutethimide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2000-05 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006371
The ClinicalTrials.gov registry entry for NCT00006371 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ketoconazole is the first listed.
NCT00006371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006371 about?
NCT00006371 is a clinical study titled "A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer". RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURP...
What is the current status of trial NCT00006371?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2000-05. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00006371?
The interventions under investigation include: ketoconazole (DRUG), therapeutic hydrocortisone (DRUG), aminoglutethimide (DRUG).
Who is sponsoring clinical trial NCT00006371?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.